Investing.com - Mersana Therapeutics reported on Monday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Mersana Therapeutics announced earnings per share of $-0.61 on revenue of $5.57M. Analysts polled by Investing.com anticipated EPS of $0.01 on revenue of $56.78M.
Mersana Therapeutics shares are down 28% from the beginning of the year and are trading at $7.09 , down-from-52-week-high.
Mersana Therapeutics shares lost 5.97% in intra-day trade the report.
Mersana Therapeutics follows other major Healthcare sector earnings this month
Mersana Therapeutics's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar